ReviewSub-cellular biochemistry2026
Fibrin as a Versatile Fibrous Biopolymer.
Review in Sub-cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrin is a fibrous biopolymer that plays a crucial role in hemostasis, thrombosis, wound healing, and various other biological functions and pathological conditions. The X-ray crystallographic structure of fibrinogen, along with computational reconstructions of missing regions and extensive biochemical and biophysical studies, has provided significant insights into the molecular mechanisms of fibrin formation, its structural organization, and its biological and mechanical properties. Upon cleavage of fibrinopeptides by thrombin, the blood protein fibrinogen is converted into fibrin monomers, which then interact through "knobs" exposed by the removal of fibrinopeptides in the central region and "holes" that are constitutively available at the ends of the molecules. The result is half-staggered, double-stranded oligomers that elongate into protofibrils, which then aggregate laterally to form fibers, and branch to create a three-dimensional network. Much has been learned about how the structure of fibrin contributes to the mechanical properties of the clot, including changes in fiber orientation, stretching, buckling, and the forced unfolding of molecular domains. Recent research into the mechanical stability of fibrin has enhanced our understanding of its rupture resistance, which is relevant to thrombotic embolization and mechanical thrombectomy. The fibrinolytic system, in which plasminogen, along with tissue-type plasminogen activator, binds to fibrin and is activated to plasmin, leads to the digestion of fibrin at specific lysine residues. Fibrin has been utilized in hemostatic fibrin sealants and as a biomaterial in tissue engineering and regenerative medicine. Despite significant advances in our understanding of these interconnected processes, much remains unknown about the molecular mechanisms underlying fibrin's biological functions, particularly concerning the molecular origins of its mechanical properties and the more complex structure and properties of hemostatic clots and pathological thrombi and their clinical implications.
Indexed as
Identifiers
41557239What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.